ENDRA Life Sciences Inc. - 8-K Filing

ENDRA Life Sciences reports Q3 2026 net loss of $1.5 million and provides update on proposed merger with Noble Africa LLC. (Items: 2.02 Results of Operations and Financial Condition On November 16, 2026, ENDRA Life Sciences Inc, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $NDRA

Read the full article at SEC EDGAR

More Regulatory news